4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · IEX Real-Time Price · USD
7.39
+0.29 (4.08%)
Jun 29, 2022 11:34 AM EDT - Market open
4.08%
Market Cap 238.70M
Revenue (ttm) 17.26M
Net Income (ttm) -81.25M
Shares Out 32.30M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,673
Open 7.03
Previous Close 7.10
Day's Range 6.94 - 7.40
52-Week Range 5.32 - 36.14
Beta n/a
Analysts Buy
Price Target 23.66 (+220.2%)
Earnings Date Aug 11, 2022

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which i... [Read more...]

Industry Biotechnology
IPO Date Dec 11, 2020
Employees 137
Stock Exchange NASDAQ
Ticker Symbol FDMT
Full Company Profile

Financial Performance

In 2021, FDMT's revenue was $18.04 million, an increase of 32.52% compared to the previous year's $13.61 million. Losses were -$71.32 million, 25.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is 23.66, which is an increase of 220.16% from the latest price.

Price Target
$23.66
(220.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted gen...

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for th...

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted gene...

Analysts Estimate 4D Molecular Therapeutics, Inc. (FDMT) to Report a Decline in Earnings: What to Look Out for

4D Molecular Therapeutics, Inc. (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ge...

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-bas...

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targ...

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ge...

4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors

EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with...

EMERYVILLE, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene t...

6 Underperforming IPO Stocks To Buy On The Dip

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last y...

Other symbols: FWRGNRDSOMICPRCTVECT

4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presenta...

EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retini...

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intra...

EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted...

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene t...

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept

4D Molecular Therapeutics Inc (NASDAQ: FDMT) has announced interim data from the Phase 1/2 trial of intravenous 4D-310 in Fabry disease patients. The Company said that 4D-310 demonstrated a manageable s...

4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Dis...

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with ...

EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...

4D Molecular To Test Its Wet AMD Gene Therapy In Patients

The FDA has signed off 4D Molecular Therapeutics' (NASDAQ: FDMT) Investigational New Drug Application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD).  The active IND enables the ini...

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene T...

Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delive...

Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-end

4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...